Latest period
−$14.38M
YoY change
+249.3%
5Y CAGR
—
Peak year (2019)
−$5.01M
Latest annual
−$54.36M
Operating Cash Flow history chart for Climb Bio (CLYM) from 2019 to 2025
Latest: −$54.36M
Operating Cash Flow growth chart for Climb Bio (CLYM) from 2019 to 2025
Latest: +249.3%
Operating Cash Flow history table for Climb Bio (CLYM) from 2019 to 2025
| 2025 | −$54.36M | +249.3% | −$38.79M | ||
| 2024 | −$15.56M | -24.5% | +$5.04M | ||
| 2023 | −$20.60M | -44.9% | +$16.77M | ||
| 2022 | −$37.37M | +3.6% | −$1.30M | ||
| 2021 | −$36.07M | +155.9% | −$21.97M | ||
| 2020 | −$14.10M | +181.5% | −$9.09M | ||
| 2019 | −$5.01M | — | — |
- 2025−$54.36M+249.3%
- 2024−$15.56M-24.5%
- 2023−$20.60M-44.9%
- 2022−$37.37M+3.6%
- 2021−$36.07M+155.9%
- 2020−$14.10M+181.5%
- 2019−$5.01M—
Operating Cash Flow values are taken from Climb Bio's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Climb Bio (CLYM)
Operating Cash Flow for Climb Bio (CLYM): headline value −$14.38M · YoY +249.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual operating cash flow for Climb Bio (CLYM) came in at −$54.36M – surged 249.3% year-over-year.
The record annual operating cash flow stands at −$5.01M, reached in 2019; the historical low of −$54.36M was recorded in 2025.
Climb Bio Operating Cash Flow by Year
Climb Bio Operating Cash Flow 2025: −$54.36M
Climb Bio operating cash flow in 2025 was −$54.36M, surged 249.3% from 2024. This figure represents the lowest annual value in the available history.
Climb Bio Operating Cash Flow 2024: −$15.56M
2024's operating cash flow for Climb Bio came in at −$15.56M, declined 24.5% below 2023.
Climb Bio Operating Cash Flow 2023: −$20.60M
Climb Bio posted operating cash flow of −$20.60M in 2023, plunged 44.9% below 2022.
Climb Bio Operating Cash Flow 2022: −$37.37M
In 2022, Climb Bio reported operating cash flow of −$37.37M, edged up 3.6% from 2021.
Climb Bio Operating Cash Flow 2021: −$36.07M
Climb Bio operating cash flow in 2021 was −$36.07M.
See more financial history for Climb Bio (CLYM).
Sector peers by Operating Cash Flow
Healthcare peers of Climb Bio (CLYM), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Climb Bio (CLYM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation